The Grants.gov Program Management Office (PMO) schedules system-wide software releases to bring its users new features and fixes. During these releases, downtime will be scheduled to deploy new enhancements. The PMO also performs scheduled maintenance on its databases and Websites in order to provide enhanced IT security and increased network reliability. The Grants.gov Calendar lists anticipated dates for both system-wide enhancements and scheduled downtimes for system maintenance.

Learn when and how to submit a reference letter, cover letter, letter of intent, letter of support and other documents. Each key letter has a distinct purpose in informing peer reviewers, NIH staff, or both. Certain letters may be necessary while others are optional or should be left out, depending on your research plans and the type of your application. The subpages contain instructions on how to use each type of letter and what is required.

NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Prior approval requests for revisions to an approved data management and sharing (DMS) plan must be submitted timely to the funding NIH Institute, Center, or Office (ICO). This functionality for NIH grants is effective from October 12, 2023, and will be used exclusively for submitting requests for updating the DMS Plan. Emails and other communications are not acceptable.

NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: An eRA Commons ID must be entered in the “Credential, e.g. agency login” field for all Senior/Key Personnel.

SBIR AND STTR FUNDING OPPORTUNITIES Non-dilutive funding for early-stage research and development. [Omnibus Solicitations] [Specific Funding Opportunities]

Department of Defense Congressionally Directed Medical Research Programs - Breast Cancer Research Program (BCRP) - Anticipated Funding Opportunity for Fiscal Year 2024 (FY24).



Although FY24 funds have not been appropriated, CDMRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. 

FY24 Pre-announcement released:

The Breast Cancer Research Program (BCRP) released a pre-announcement for the following funding opportunities:

·       Breakthrough Award Levels 1 and 2

·       Breakthrough Award Level 3

·       Breakthrough Award Level 4

·       Era of Hope Scholar Award

·       Clinical Research Extension Award

·       Transformative Breast Cancer Consortium Development Award

·       Transformative Breast Cancer Consortium Award

Department of Defense Congressionally Directed Medical Research Programs - Ovarian Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2024 (FY24) Although FY24 funds have not been appropriated, CDMRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. 

FY24 Pre-announcements released:

The Ovarian Cancer Research Program (OCRP) released a pre-announcement for the following funding opportunities:

·       Pilot Award

·       Investigator- Initiated Research Award

·       Clinical Trial Award

·       Clinical Trial Translational Endpoints Award ** (NEW)

·       Ovarian Cancer Academy – Leadership Award ** (NEW)

·       Ovarian Cancer Academy – Early-Career Investigator Award

·       Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award** (NEW)

Department of Defense Congressionally Directed Medical Research Programs - Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2024 (FY24). Although FY24 funds have not been appropriated, CDMRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. 

FY24 Pre-announcements released:

The Amyotrophic Lateral Sclerosis Research Program (ALSRP) released a pre-announcement for the following funding opportunities:

·       Clinical Outcomes and Biomarkers Award

·       Pilot Clinical Trial Award

·       Therapeutic Development

·       Therapeutic Idea Award

The Peer Reviewed Alzheimer’s Research Program (PRARP) released a pre-announcement for the following funding opportunities:

·       Transforming Care Award

·       Transforming Diagnosis Award

·       Transforming Research Award

The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this grant is to fund physicians during the transition from a fellowship program to a faculty appointment. This is a mentored award and the research project is conducted under the guidance of a scientific mentor. Applications in all areas of cancer research are accepted from U.S. and international applicants. The YIA is a one-year grant totaling $50,000 that supports personnel and/or research expenses, and travel to attend the Conquer Cancer Grants & Awards Ceremony at the ASCO Annual Meeting. Applicants who are selected to receive a YIA are allowed to receive other grants from other funding agencies. The details of eligibility, application instructions and applicable due dates (January 31 and March 14, 2024) can be found here.

Internal Deadline: January 31, 2024

Foundation LOI Deadline: February 15, 2024

Amount: $1,035,000/3 years (includes 15% IDC)

About: Only chemical biology research.  Chemical biology is defined as the interface between chemistry and biology.  The criteria are intentionally broad so as not to disqualify potentially innovative and groundbreaking projects. Projects must be relevant to the foundation’s mission: support scientist Principal Investigators (“PIs”) with creative ideas in selected scientific research fields with the mission of seeking discoveries/solutions and development of high impact science. Goals: breakthrough treatment solutions for patients, support development of promising and established scientists, strong relationships with the community. Applications will be judged on their consideration and understanding of the technology required for completion.

Eligibility: MD and/or PhD; new applicant or project; 15 years or less since independent academic position; not engaged with Ono Pharmaceutical Co. or Foundation; new idea rather than amplify current work; not a healthcare professional (MD w/o active state medical license is eligible); serving on healthcare formulary or similar committee not eligible.

Note: AECOM may nominate up to two (2) candidates.  The deadline for submission of preliminary applications for internal review by the Einstein Awards Committee is Wednesday January 31, 2024. Please email a single (one) PDF following the outline below to: Audrey McInerney (amcinerney@montefiore.org).

LOI outline:

1. Contact Information
2. Abstract – no more than 150 words. The abstract should provide a brief description of the PI’s project’s goal(s).
3. Vision of the Proposed Research – one-page single-spaced 12pt font. CV and reference list do not contribute to word/page limit. Figures may be included but should not exceed an additional two pages. If there is a figure that best explains your project, please indicate which one.
4. Curriculum vitae (“CV”)

• The CV may not exceed five pages.
• NIH Biosketch format is preferred. The new format extends the page limit for the biosketch from four to five pages and allows researchers to describe up to five of their most significant contributions to science, along with the historical background that framed their research. Investigators can outline the central findings of prior work and the influence of those findings on the investigator’s field.
• The CV must disclose all grants or awards currently received or pending which would be relevant to the Proposed Research.

The College has been invited to submit TWO candidates for the Charles H. Revson Senior Fellowship in Biomedical Science for 2024.  This program seeks to support New York City's most promising third- and fourth-year post-doctoral researchers in the biomedical sciences. Up to eight awards are made each year. Fellows may be engaged in experimental basic research in any area of biomedical science. The Revson Fellowship provides an annual stipend of 125% of the current NIH level, and fringe benefits, plus operational support of $10,000 and a travel and conference fund of up to $3,500. Awards will be made for two years, with second-year award funding contingent upon satisfactory progress.          

Fellows may officially begin the fellowship between July 2024 and October 2024. 

Eligibility - All applicants must:

...have completed one or more of the following degrees or its equivalent: M.D., Ph.D. 

...have already completed two years doing postdoctoral training in basic biomedical research. Candidates must have entered their postdoctoral training at Einstein between June 1, 2021 and August 31, 2022. (Dates are strict; no exceptions made)

[Note: While individuals with postdoctoral training prior to arriving at Einstein are technically eligible, the Foundation is particularly interested in candidates currently in their first post-doctoral position.]

...be working under the guidance of a mentor (a scientist) capable of providing mentorship to the Fellow.

...be citizens or legal residents of the U.S. (Non-citizens must hold appropriate visa documentation that is valid for the course of the fellowship.) Permanent resident status is not necessary. 

...agree to not take part in any other fellowship program during the course of the Charles H. Revson Senior Fellowship in Biomedical Science. 

In order to implement the application process for this competition, eligible postdoctoral investigators and their faculty advisors are invited to submit preliminary applications for review by the Awards Committee. From among these applications, the Committee will make recommendations and our Dean will select the candidate(s) who will be invited to submit full proposals to the foundation. The foundation deadline is March 1,2024. 

The deadline for submission of preliminary applications is 5 PM, Monday, February 12, 2024. Please submit the application as a single PDF file email attachment to indranil.basu@einsteinmed.edu  

1.  The application is to consist of:

a. Candidate Profile Form.  Download from:  

https://www.einsteinmed.edu/docs/administration/grant-support/cpffillable.pdf  

b. A written proposal (3 pages maximum) describing the work to be proposed.  One additional page of references may be included. 

c. A letter of recommendation written by the advisor/mentor (TWO pages maximum).  

d. The candidate's complete curriculum vitae. The recommended format for curriculum vitae may be found at  

http://www.einsteinmed.edu/administration/academic-appointments/cv.aspx   

e. The mentor/advisor's NIH Biosketch and Other Support pages. 

Please note that our 2 nominees will submit a final 5 -page application (1.5 spaced in 11-point type) and 3 letters of recommendation (one of these from the sponsor/mentor). The 5-page limit refers only to the proposal itself. The required CV and letters can use additional pages.  

If you have any questions concerning this award or the application procedure, please contact Dr. Indranil Basu at the Office of Grant Support at indranil.basu@einsteinmed.edu. 

The Feldstein Medical Foundation (FMF) is a private, not-for-profit foundation created to promote and advance medical research, including new or innovative areas of research or smaller, seed-type projects. 

They are specifically interested in funding: 

• Promising junior investigators (Assistant Professor level) with a history of some prior funding. 
• New or innovative research. 
• Research in areas where FMF funding will have the maximum beneficial impact on health or healthcare practice for significant populations. 
• Research that may lead to significant advancements in scientific knowledge.

Einstein has been invited to submit TWO candidates: one in the category of Basic Science Research and one in Translational Research/Clinical Research/Medical Education Research. Accepted projects will be funded for a period of up to 1 year, with total costs of up to $80,000 (a maximum of 10% indirect costs may be included in that total). 

All applicants must: 

• Have a doctoral degree (or equivalent) in a field related to medicine, nursing, public health, health care or biomedical sciences 
• Have an Einstein faculty appointment. 
• Demonstrate the research skills, knowledge, and resources to carry out the research successfully. Junior researchers with a history of prior funding are encouraged to apply.

The deadline for submission of preliminary applications to the Office of Grant Support for internal review by Einstein’s Awards Committee is 5 PM, Tuesday, February 27, 2024. For the internal review, please send ONE PDF file containing the following as an email attachment to Indranil.basu@einsteinmed.edu - 

• Candidate Profile Form – click here. 
• A statement outlining the applicant’s career potential and the Department’s plans for his/her future to be obtained from the Department Chairperson, limited to no more than TWO single-spaced pages. This should include the importance of the investigator to the proposed research and the institution’s commitment to that research project. 
• A written proposal that must include the title, background, goals, procedures, and significance of the proposed research project to be carried out during the grant period, limited to no more than three single-spaced pages, plus one additional page (single-spaced) for references with titles included. The font should be 11-point or larger. Figure legends can use smaller fonts. You must indicate in which of the two categories your application fits. 
• A complete curriculum vitae and bibliography. Include invited presentations, but not abstracts. Please click here to find the recommended format for curriculum vitae. 
• Information about present and pending grant support with amounts requested or approved, annual amounts, and duration of award.

For any additional information about FMF and the external application process, or if you have any questions concerning this award or the internal application procedure, please contact Indranil.basu@einsteinmed.edu.

The purpose of this award is to support highly innovative, high-impact projects leading to critical discoveries or major advancements in the field of cardiovascular and/or cerebrovascular research. The annual award amount is $100,000, including 10 percent indirect cost. Duration of this award will be three years with a total award amount of $300,000. The proposal deadline is February 15, 2024 (3 pm CT). For eligibility criteria, restrictions, peer review criteria and other details, please click here.

The Sontag Foundation, Ponte Vedra Beach, Florida, is one of the largest private funders of brain cancer research in North America. The Foundation is soliciting applications for its Distinguished Scientist Award. $750,000 in funding over 5 years is open to early career investigators throughout the United States. The goal of this funding initiative is to change the paradigm of brain cancer research by building a community of outstanding scientists whose pioneering approaches have the potential to make significant advances in the field of brain cancer/brain tumors. The applications are due on March 13, 2024 at 11:59pm ET. Please click here to find the grant guidelines.

Eligibility - Applicants must hold a doctoral degree in a discipline with applicability to brain cancer research. Applicants must have received their first independent faculty appointment no earlier than March 1, 2019 and no later than January 1, 2024 at a tax-exempt academic, research, or medical institution within the United States or an equivalent institution in Canada. If the institution grants tenure, the qualifying appointment must be on tenure track. More than one individual from the same institution may apply for this award. This grant does not support clinical trials research. For further inquiries, please contact Shandra Koler, Senior Program Officer, Email: skoler@sontagfoundation.org and phone: 904-274-8557.

The Career Development Award (CDA) provides research funding to clinical investigators who have received their initial faculty appointment, as they work to establish an independent clinical cancer research program. This is a mentored award and the research project is conducted under the guidance of a scientific mentor. The research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed. Applications in all areas of cancer research are accepted from U.S. and international applicants.The CDA is a three-year grant totaling $200,000 that supports personnel and/or research expenses, and travel to attend the Conquer Cancer Grants and Awards Ceremony at the ASCO Annual Meeting. The details of eligibility, application instructions and applicable due date (March 14, 2024) can be found here.